Early trial tests drug combo to shrink rare, tough nerve tumors
NCT ID NCT04465643
Summary
This small, early-phase study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) before standard surgery or other treatments was safe and feasible for people with a rare, aggressive type of nerve tumor. The trial involved 13 participants with these tumors, often linked to a genetic condition called Neurofibromatosis Type 1 (NF1). The main goals were to check for side effects and see if the treatment approach was practical.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NERVE SHEATH TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Medical Institution
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.